Results 71 to 80 of about 10,485 (198)

Mechanical Phenotyping of MG63s Following Vibrational Stimulation

The FASEB Journal, Volume 40, Issue 9, 15 May 2026.
Mechanical Phenotyping of MG63s Following Vibrational Stimulation, *Mr. Rui Pedro Pereira Sousa, Prof Stuart Reid, Prof Matthew J. Dalby, Dr. Melanie Jimenez and *Dr. Peter G. Childs. Summary of the use of a high throughput mechanical phenotyping technique, Real‐Time Deformability Cytometry (RT‐DC) to observe mechanical changes in an osteogenic model ...
Rui Pedro Pereira Sousa, Stuart Reid, Matthew J. Dalby, Melanie Jimenez, Peter G. Childs   +4 more
wiley   +1 more source

A Phase 3 Multicenter, Double‐Blind Study Comparing Efficacy, Safety, Immunogenicity, and Pharmacokinetics of Alkem's Biosimilar Teriparatide Versus Reference Teriparatide in Postmenopausal Osteoporosis

Aging Medicine
Objective The primary purpose of this study was to compare the efficacy and safety of proposed biosimilar teriparatide with reference teriparatide in patients of postmenopausal osteoporosis.
Nitin Kapoor, Thomas Paul, Rajeshwar Nath Srivastava, Saurabh Singh, Sunil Maheshwari, Vishal Patil, Awadhesh Kumar Yadav, Girish Bhatia, Sushil H. Mankar, Joe Joseph Cherian, Surabhi Maheshwari, Sudeepti Srivastava, Dattatray Pawar, Roshan Pawar, Amol Aiwale, Amitrajit Pal, Yogesh Rane, Vinayaka Shahavi, Akhilesh Sharma   +18 more
doaj   +1 more source

Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis

, 2013
Robin K DoreDavid Geffen School of Medicine, University of California, Los Angeles, CA, USAAbstract: Glucocorticoids are commonly prescribed medications to treat multiple diseases across many medical specialties.
Dore RK
core  

Teriparatide - Indications beyond osteoporosis

, 2012
Osteoporosis is a condition of impaired bone strength that results in an increased risk of fracture. The current and most popular pharmacological options for the treatment of osteoporosis include antiresorptive therapy, in particular, oral ...
Vishal Gupta, Marilyn Lee Cheng, MarilynLee Cheng   +2 more
core   +1 more source

Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis

Arthritis &Rheumatology, Volume 78, Issue 5, Page 1176-1183, May 2026.
Objective Transition from long‐term denosumab (Dmab) to parathyroid hormone‐analogs or romosozumab (Romo) might expose patients to the risk of the so‐called rebound phenomenon. Adding Romo to Dmab might represent an option in patients experiencing a fracture while on Dmab.
Giovanni Adami, Francesco Pollastri, Angelo Fassio, Filippo Montanari, Anna Piccinelli, Camilla Benini, Emma Pasetto, Carmen Dartizio, Davide Gatti, Maurizio Rossini, Ombretta Viapiana   +10 more
wiley   +1 more source

Review of the Literature on the Impact of Teriparatide Use on Bone Healing

Quality in Sport
  Introduction Fractures, especially hip fractures, represent a growing health issue in aging societies. Recovery of mobility after such an injury can be prolonged and not always complete, affecting patients' quality of life.
Larysa Bielecka
doaj   +1 more source

Teriparatide in the management of osteoporosis

, 2008
Donald Bodenner, Carolyn Redman, Ann RiggsDepartment of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USAAbstract: Fracture of the hip is frequently a catastrophic event in the elderly, often resulting in death within a year ...
Ann Riggs, Donald Bodenner, Carolyn Redman   +2 more
core  

Investigation of Bisphosphonate Therapy for Osteoporosis: A Single‐Center Cross‐Sectional Study

Journal of General and Family Medicine, Volume 27, Issue 3, May 2026.
ABSTRACT Background This study aimed to examine the management of bisphosphonate (BP) therapy for osteoporosis in Japan, focusing on treatment duration, dual‐energy X‐ray absorptiometry (DXA) assessment status, therapy despite renal impairment, and history of atypical femoral fracture (AFF).
Taku Harada, Shintaro Kosaka
wiley   +1 more source

Knochenanabole Therapie mit Teriparatid [Bone anabolic treatment with Teriparatide].

, 2012
The recombinant amino-terminal fragment of human parathyroid hormone (Teriparatide) is a bone anabolic agent which reduces fracture risk by increasing bone mass and improving bone microarchitecture.
Lamy, O.
core   +1 more source

Efficacy and safety of denosumab and teriparatide versus oral bisphosphonates to treat postmenopausal osteoporosis: a systematic review and meta-analysis

Frontiers in Endocrinology
Study DesignA systematic review and Meta-analysisObjectiveTo compare the efficacy and safety of denosumab and teriparatide versus oral bisphosphonates to treat postmenopausal osteoporosis.Summary of Background DataWhile bisphosphonates have historically ...
Jia Yang, Xiaobo Guo, Zhongning Cui, Huikang Guo, Jia-Nan Dong   +4 more
doaj   +1 more source